Skip to content
    Gilead Sciences logo

    Gilead Sciences

    Foster City, California, United StatesFounded 1987
    www.gilead.comLinkedIn
    Biotech & Life SciencesHealthcare

    Gilead Sciences is a biopharmaceutical company focused on antiviral drugs, oncology, and cell therapy. As a corporate venture investor, it has made over 40 investments in life sciences companies across stages.

    Their most common stage is series-b (50% of deals). Average disclosed round size is $61.9M (across 22 rounds with reported amounts).

    Find people at Gilead Sciences on Goldilocks AI

    Portfolio

    20

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    0

    Team

    Cindy Perettie

    Cindy Perettie

    Executive Vice President, Kite

    Flavius Martin, MD

    Flavius Martin, MD

    Executive Vice President, Research

    Jyoti Mehra

    Jyoti Mehra

    Executive Vice President, Human Resources

    KC

    Keeley Cain Wettan

    Executive Vice President & General Counsel, Legal and Compliance

    Stacey Ma

    Stacey Ma

    Executive Vice President, Pharmaceutical Development and Manufacturing

    Andrew Dickinson

    Andrew Dickinson

    Chief Financial Officer

    Daniel O’Day

    Daniel O’Day

    Chairman and Chief Executive Officer, Gilead Sciences

    Dietmar Berger, MD, PhD

    Dietmar Berger, MD, PhD

    Chief Medical Officer

    Johanna Mercier

    Johanna Mercier

    Chief Commercial & Corporate Affairs Officer

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    26 investments
    CompanyRoundAmountDate
    KKyverna TherapeuticsSeries B$60MAug 2023
    Curebase logoCurebaseSeries B$40MMay 2023
    Curebase logoCurebaseSeries B$40MMay 2022
    Curebase logoCurebaseSeries B$40MJan 2022
    Curebase logoCurebaseSeries A—Jan 2022
    Barinthus Biotherapeutics logoBarinthus BiotherapeuticsSeries B$168MMar 2021
    Vaccitech logoVaccitechSeries B$168MMar 2021
    KKyverna TherapeuticsSeries A$25MJan 2020
    Kyverna logoKyvernaSeries A$25MJan 2020
    Tmunity logoTmunitySeries B$75MOct 2019
    LLyndra Therapeutics Inc.Series C$55MJan 2019
    AAlloVirSeries B$120MJan 2019
    LLyndra Therapeutics Inc.Series B$55MJan 2019
    Goldfinch Bio logoGoldfinch BioSeries A$55MJan 2019
    GGlympse BioSeries A$22MOct 2018
    Tmunity logoTmunitySeries A—Apr 2018
    Pionyr Immunotherapeutics logoPionyr ImmunotherapeuticsSeries B$62MDec 2017
    EEpiTherapeuticsSeed—Dec 2010
    Precision BioSciences logoPrecision BioSciencesSeries B$110M—
    Tentarix Biotherapeutics logoTentarix BiotherapeuticsSeries B$35M—
    HiFiBiO Therapeutics logoHiFiBiO TherapeuticsSeries C$67M—
    LLyndraSeries B$55M—
    EExavir TherapeuticsSeed$4M—
    HHiFiBiOSeries C——
    Glympse logoGlympseSeries A$22M—
    Page 1 of 2

    Top Co-Investors

    Polaris Partners4 shared
    The Invus Group, LLC4 shared
    Westlake Village BioPartners4 shared
    Industry Ventures3 shared
    GGV Capital3 shared
    Stanford's StartX Fund3 shared
    Acrew Capital3 shared
    Xfund3 shared
    Positive Sum3 shared
    Bold Capital Partners3 shared
    World Innovation Lab3 shared
    Hopu Investments3 shared
    LYFE Capital3 shared
    Gaingels2 shared
    Korea Investment Partners2 shared
    Osage University Partners2 shared
    Future Planet Capital2 shared
    Northpond Ventures2 shared
    Insight Partners2 shared
    Sofinnova Partners2 shared

    Last updated: 20 October 2026